|
|
|
| Effect of Alprostadil Combined with Aspirin on Vascular Endothelial Function in Coronary Slow Blood flow in Elderly Patients with Angina Pectoris |
| HASIgaowa, Wujisiguleng, Liu Donghua |
| Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia Hohhot 010059, China |
|
|
|
|
Abstract Objective: To study the effect of alprostadil combined with aspirin on vascular endothelial function in coronary slow blood flow in elderly patients with angina pectoris. Methods: 115 patients with coronary slow flow angina admitted to our hospital from January 2015 to October 2018 were randomly divided into observation group (60 cases) and control group (55 cases). On the basis of routine treatment, the control group was given aspirin treatment, and observation group was treated with Alprostadil for 3 consecutive months. The total effective rate of the observation group was significantly higher than that of the control group (P<0.05). No, ET-1, FMD, the number and duration of angina pectoris attack per day, the number of corrected tmit blood flow frames were statistically significant (P>0.05). Results: After treatment, the total effective rate in the observation group was significantly higher than that of the control group (P<0.05). There were significant differences in serum nitric oxide (NO), endothelin-1 (ET-1), Endothelial Dependent Vasodilation Function (FMD), the number and duration of angina pectoris daily attacks and Corrected TMIT Blood Flow Frames between the two groups at interblock, different time points (P<0.05), and they all have interaction (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: Alprostadil combined with aspirin has a significant effect in the treatment of elderly patients with coronary slow flow angina, which can effectively improve the endothelial function, promote the recovery of coronary blood flow, relieve clinical symptoms, and has a high clinical application value.
|
|
|
|
|
|
[1] 何永福,孙林,林志.冠状动脉慢血流现象病理生理机制及治疗进展[J].心血管病学进展,2018,39(3):448~452.
[2] 朱曙光,曹蘅.冠状动脉慢血流研究进展[J].安徽医药,2018,22(12):2304~2306.
[3] Jin Z, Tan Q, Sun B. Telmisartan ameliorates vascular endothelial dysfunction in coronary slow flow phenomenon (CSFP)[J]. Cell Biochem Funct, 2018, 36(1): 18~26.
[4] 李想,朱国斌,周学敏.前列地尔在心血管疾病的临床应用[J].中华临床医师杂志(电子版),2017,11(2):288~291.
[5] 张健维,高建军,刘德林,等.老年冠心病心绞痛患者急性发作期应用前列地尔的临床观察[J].中国处方药,2018,16(11):146~147.
[6] 韩会来,尹红,吕国芬,等.前列地尔对经皮冠状动脉介入治疗术后心肌梗死患者冠状动脉血流、脂质代谢及氧化应激因子水平的影响[J].中国卫生检验杂志,2018,28(4):438~440.
[7] 陈玄祖.冠状动脉慢血流现象的影响因素及临床研究[J].中国循证心血管医学杂志,2018,10(6):743~745. |
|
|
|
2019, Vol. 25 
